This webinar will be hosted live and available on-demand

Monday, November 28, 2022 
11:00 AM Eastern Time 

Cell therapies, particularly engineered T cells, are effective treatments for blood cancers, but have limited efficacy in solid tumors because of the immunosuppressive features of the tumor microenvironment. Researchers are applying insights about the mechanisms of molecular and chromatin remodeling before and during T cell activation and fate determination to improve immunotherapies.

In this webinar brought to you by The Scientist, Douglas Green will discuss how scientists leverage discoveries in T cell biology to develop effective CAR T cell therapies for solid tumors.

Topics to be covered 

  • Molecular mechanisms promoting memory T cell fate
  • Strategies to improve cancer immunotherapies
Douglas R. Green, PhD 

Douglas R. Green, PhD
Chair, Department of Immunology  
Co-Leader, Cancer Biology Program
St. Jude Children’s Research Hospital

Sponsored by